IL161852A0 - Phenyl substituted triazoles and their use as selective inhibitors of akl5 kinase - Google Patents

Phenyl substituted triazoles and their use as selective inhibitors of akl5 kinase

Info

Publication number
IL161852A0
IL161852A0 IL16185202A IL16185202A IL161852A0 IL 161852 A0 IL161852 A0 IL 161852A0 IL 16185202 A IL16185202 A IL 16185202A IL 16185202 A IL16185202 A IL 16185202A IL 161852 A0 IL161852 A0 IL 161852A0
Authority
IL
Israel
Prior art keywords
akl5
kinase
phenyl substituted
selective inhibitors
substituted triazoles
Prior art date
Application number
IL16185202A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of IL161852A0 publication Critical patent/IL161852A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL16185202A 2001-11-15 2002-11-14 Phenyl substituted triazoles and their use as selective inhibitors of akl5 kinase IL161852A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0127430.7A GB0127430D0 (en) 2001-11-15 2001-11-15 Compounds
PCT/EP2002/013482 WO2003042211A1 (en) 2001-11-15 2002-11-14 Phenyl substituted triazoles and their use as selective inhibors of akl5 kinase

Publications (1)

Publication Number Publication Date
IL161852A0 true IL161852A0 (en) 2005-11-20

Family

ID=9925832

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16185202A IL161852A0 (en) 2001-11-15 2002-11-14 Phenyl substituted triazoles and their use as selective inhibitors of akl5 kinase

Country Status (17)

Country Link
US (1) US20050014938A1 (ru)
EP (1) EP1444232A1 (ru)
JP (1) JP2005518352A (ru)
KR (1) KR20050044476A (ru)
CN (1) CN1608065A (ru)
BR (1) BR0214160A (ru)
CA (1) CA2467267A1 (ru)
GB (1) GB0127430D0 (ru)
HU (1) HUP0402227A2 (ru)
IL (1) IL161852A0 (ru)
IS (1) IS7252A (ru)
MX (1) MXPA04004593A (ru)
NO (1) NO20042244L (ru)
PL (1) PL369605A1 (ru)
RU (1) RU2004117862A (ru)
WO (1) WO2003042211A1 (ru)
ZA (1) ZA200403487B (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097639A1 (en) * 2002-05-15 2003-11-27 Smithkline Beecham Corporation Benzoxazine and benzoxazinone substituted triazoles
GB0217780D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
GB0217787D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd C ompounds
ATE343572T1 (de) * 2002-08-09 2006-11-15 Lilly Co Eli Benzimidazole und benzothiazole als inhibitoren der map-kinase
WO2005026344A1 (ja) * 2003-09-11 2005-03-24 Hubit Genomix, Inc. 硬化をもたらす増殖性疾患の検出方法及びキット、硬化をもたらす増殖性疾患の予防及び／又は治療剤、ならびに硬化をもたらす増殖性疾患の予防及び／又は治療に有効な物質を同定する方法及びキット
US7863310B2 (en) 2004-02-03 2011-01-04 Eli Lilly And Company Kinase inhibitors
AU2005267798A1 (en) * 2004-07-28 2006-02-09 Irm Llc Compounds and compositions as modulators of steroid hormone nuclear receptors
BRPI0609650A2 (pt) * 2005-03-25 2010-04-20 Tibotec Pharm Ltd inibidores heterobicìlicos de hvc
AR056347A1 (es) 2005-05-12 2007-10-03 Tibotec Pharm Ltd Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
DE102005061840A1 (de) 2005-12-23 2007-06-28 Merck Patent Gmbh Triazolderivate
PT2044025E (pt) 2006-06-30 2012-12-17 Novartis Ag Derivados de quinolinona e suas composições farmacêuticas
CA2665438C (en) 2006-10-04 2014-12-02 Tibotec Pharmaceuticals Ltd. Carboxamide 4-[(4-pyridyl)amino]pyrimidines useful as hcv inhibitors
EP1921072A1 (en) * 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,3-Triazole derivatives as cannabinoid-receptor modulators
US7678819B2 (en) * 2006-12-07 2010-03-16 The Trustees Of The University Of Pennsylvania Acetylene derivatives and their use for binding and imaging amyloid plaques
US8877676B2 (en) 2008-07-09 2014-11-04 Postech Academy-Industry Foundation Heterogeneous copper nanocatalyst and manufacturing methods thereof
KR101076628B1 (ko) 2008-07-09 2011-10-27 포항공과대학교 산학협력단 불균일 구리 나노 촉매 및 그 제조방법
US8586581B2 (en) 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
CN102443009B (zh) * 2010-09-30 2014-04-16 山东轩竹医药科技有限公司 并环激酶抑制剂
JP6445971B2 (ja) 2012-05-30 2018-12-26 コーネル ユニヴァーシティー ヒト羊水由来細胞からの機能的かつ耐久性のある内皮細胞の生成
JP6529486B2 (ja) 2013-06-05 2019-06-12 バイオタイム インク．Ｂｉｏｔｉｍｅ Ｉｎｃ． 哺乳動物種における誘導組織再生のための組成物および方法
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
WO2022251359A1 (en) * 2021-05-26 2022-12-01 Theravance Biopharma R&D Ip, Llc Bicyclic inhibitors of alk5 and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2341370A1 (en) * 1998-08-20 2000-03-02 Smithkline Beecham Corporation Novel substituted triazole compounds
EP1169317B1 (en) * 1999-04-09 2003-01-15 SmithKline Beecham Corporation Triarylimidazoles
CO5271680A1 (es) * 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
GB0007405D0 (en) * 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
EP1274424A4 (en) * 2000-04-12 2003-09-17 Smithkline Beecham Corp CONNECTIONS AND PROCEDURE
GB0027987D0 (en) * 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds

Also Published As

Publication number Publication date
RU2004117862A (ru) 2006-01-10
HUP0402227A2 (hu) 2005-02-28
CA2467267A1 (en) 2003-05-22
US20050014938A1 (en) 2005-01-20
CN1608065A (zh) 2005-04-20
MXPA04004593A (es) 2004-08-13
ZA200403487B (en) 2006-05-31
KR20050044476A (ko) 2005-05-12
WO2003042211A1 (en) 2003-05-22
BR0214160A (pt) 2004-09-28
PL369605A1 (en) 2005-05-02
EP1444232A1 (en) 2004-08-11
JP2005518352A (ja) 2005-06-23
GB0127430D0 (en) 2002-01-09
NO20042244L (no) 2004-07-13
IS7252A (is) 2004-05-06

Similar Documents

Publication Publication Date Title
IL161852A0 (en) Phenyl substituted triazoles and their use as selective inhibitors of akl5 kinase
IL157659A0 (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
HK1068874A1 (en) Heterocyclic compounds and methods of use
EG27049A (en) P38 inhibitors and methods of use thereof
MXPA03006420A (es) Diaminotiazoles.
EP1383743A4 (en) DOUBLE INHIBITORS OF PDE 7 AND PDE 4
PL378432A1 (pl) Inhibitory p38 i sposoby ich zastosowania
GB0025782D0 (en) Use of inhibitors
EP1363702A4 (en) PROCESS FOR INHIBITING KINASES
HK1053832A1 (zh) 蛋白激酶抑制劑
EP1601357A4 (en) HETEROCYCLIC KINASE INHIBITORS: METHOD OF USE AND SYNTHESIS
IL174431A0 (en) Substituted benzazoles and use thereof as inhibitors of raf kinase
HK1072545A1 (en) Novel inhibitors of kinases
IL149106A0 (en) Therapeutic use of selective pde10 inhibitors
EP1448218A4 (en) BETA SECRETASE INHIBITORS AND METHODS OF USE
AU8323701A (en) Inhibitors of p38
EP1390052A4 (en) INHIBITION OF JUN KINASE
HK1077520A1 (zh) 用作p38促細胞分裂原活化蛋白激酶抑制劑的吲哚類衍生物
AU9625501A (en) Substituted azole derivatives as inhibitors of corticotropin releasing factor
AU2003210983A8 (en) Kinase inhibitors and methods of use thereof
HUP0401641A3 (en) Use of substituted diazonine derivatives as phosphorodiesterase iv inhibitors
IL160230A0 (en) Use of il-18 inhibitors
EP1631145A4 (en) P38 KINASEHEMMER COMPOSITION AND METHOD FOR THEIR USE
SI1448564T1 (sl) Substituirane indolizinu podobne spojine in postopki uporabe
AU2002342650A1 (en) Nitrogen-containing heterocyclic compounds and their use as raf inhibitors